RxDoctor Payments Data

Christopher Agro

Optometrist · Enfield, CTNPI 1912977380

Payments from drug & device makers

$2,154in general payments, 2019–2025

Across 78 payments — averaging $27.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$591
  • Sun Pharmaceutical Industries Inc.$454
  • Novartis$238
  • AbbVie$177
  • Bausch & Lomb Americas Inc.$168
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$140
  • plus $386 from 7 others

What the payments were for

  • Food & beverage$2,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,154 in reported general payments places this provider in the 70th percentile of 574 optometrist providers in Connecticut.

See all optometrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$53,216
Medicare patients
206
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine36$53,175
XiidraLifitegrast21$33,187
VyzultaLatanoprostene Bunod46$26,000
RocklatanNetarsudil Mesylat/Latanoprost34$20,890
LumiganBimatoprost32$16,654
RhopressaNetarsudil Mesylate24$12,971
Cyclosporine18$8,574
Travoprost25$2,890
Latanoprost103$1,583
Dorzolamide Hcl23$395
Azelastine Hcl12$351
Timolol Maleate33$339
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$177$69,82968 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$168$59,18767 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$20$33,86158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 574 optometrist providers in Connecticut.

Other optometrist in Enfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →